Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pegcetacoplan versus sham in geographic atrophy secondary to age-related macular degeneration
2018-001436-22Phase 3Unknown
- Sponsor
- Apellis Pharmaceuticals
- Start
- Sep 2018
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegcetacoplan in age-related macular degeneration (AMD) (2 arms), sponsored by Apellis Pharmaceuticals. Primary endpoint: Change from baseline to Month 12 in total area of geographic atrophy lesions. Status: unknown.
02
Drugs
pegcetacoplan
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2018-001436-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001436-22.